ONCAlert | 2018 ASCO Annual Meeting

Efficacy Results for LOXO-101 in TRK Fusion Cancers

David Hyman, MD
Published Online: 7:49 PM, Sat June 3, 2017

David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.